Modified FOLFIRINOX

DRUG12 trials

Sponsors

Cancer Institute Hospital, Gifu University Hospital, Emory University, AbbVie, Onconic Therapeutics Inc.

Conditions

Advanced Gastrointestinal, Biliary Tract, and Pancreatic CancersBorderline Resectable Pancreatic CancerCancer of PancreasCancer of the PancreasHigh-Risk Resectable Pancreatic CancerLocally Advanced Pancreatic AdenocarcinomaMetastatic Pancreatic AdenocarcinomaNeoplasms, Pancreatic

Phase 1

Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer

CompletedNCT01446458

Emory UniversityCancer of Pancreas, Cancer of the Pancreas, Neoplasms, Pancreatic +2

Start: 2011-11-30End: 2015-03-31Updated: 2016-03-22

Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis

TerminatedNCT04807972

AbbViePancreatic Cancer

Start: 2021-05-28End: 2024-03-25Updated: 2025-01-07

Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer

RecruitingNCT05257993

Onconic Therapeutics Inc.Pancreatic Ductal Adenocarcinoma

Start: 2022-03-30End: 2030-04-01Target: 71Updated: 2026-04-13

Trial of Devimistat in Combination With Modified FOLFIRINOX in Patients With Metastatic Adenocarcinoma of the Pancreas

WithdrawnNCT05926206

University of Michigan Rogel Cancer CenterMetastatic Pancreatic Adenocarcinoma

Start: 2023-07-31End: 2027-01-31Updated: 2023-08-02

A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

Active, not recruitingNCT06360354

AmgenAdvanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers

Start: 2024-05-29End: 2026-11-30Updated: 2026-06-01

Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer

Not yet recruitingNCT07829185

University of OklahomaPancreatic Ductal Adenocarcinoma (PDAC)

Start: 2026-12-01End: 2030-12-01Target: 30Updated: 2026-09-18

Repurposing Mefloquine for Pancreatic Cancer Treatment

Not yet recruitingNCT07875907

University of FloridaPancreatic Ductal Adenocarcinoma

Start: 2026-11-01End: 2031-01-01Target: 36Updated: 2026-10-15

Phase 2

Phase II trial of modified FOLFIRINOX (irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin) in patients with untreated metastatic pancreatic cancer

Active, not recruitingJPRN-UMIN000013301

Cancer Institute Hospitaluntreated metastatic pancreatic cancer

Start: 2014-02-20Target: 65Updated: 2026-06-29

Phase II study of modified FOLFIRINOX as first-line for advanced pancreatic cancer

Active, not recruitingJPRN-UMIN000015376

Gifu University Hospitaladvanced pancreatic cancer

Start: 2014-10-01Target: 28Updated: 2026-06-29

Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma

RecruitingNCT06048484

Gulam ManjiPancreatic Ductal Adenocarcinoma

Start: 2024-05-10End: 2027-04-01Target: 60Updated: 2026-02-27

Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer

RecruitingNCT06850623

EXACT Therapeutics ASLocally Advanced Pancreatic Adenocarcinoma

Start: 2025-06-19End: 2027-07-15Target: 25Updated: 2026-10-13

Surufatinib in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemotherapy for Neoadjuvant Therapy of HRPC or BRPC

Not yet recruitingNCT07833241

Shanghai Zhongshan HospitalBorderline Resectable Pancreatic Cancer, High-Risk Resectable Pancreatic Cancer

Start: 2026-09-01End: 2029-09-01Target: 56Updated: 2026-09-22

Related Papers

Safety and efficacy of nesuparib (JPI-547) with gemcitabine-nab-paclitaxel (GemAbraxane) or modified FOLFIRINOX (mFOLFIRINOX) in patients with locally advanced or metastatic PDAC: Results from an ongoing phase Ib/II study.

Journal of Clinical Oncology2026-05-27

Abstract 7065: Targeting MTAP-deleted/KRAS mutant cancers using RAS inhibitors in combination with AMG 193, an MTA-cooperative PRMT5 inhibitor.

Cancer Research2026-04-03

A phase 2 study to investigate the efficacy and safety of acoustic cluster therapy with modified FOLFIRINOX in patients with locally advanced pancreatic cancer.

Journal of Clinical Oncology2026-01-10

Abstract A068: A phase 2 study to investigate the efficacy and safety of acoustic cluster therapy with modified FOLFIRINOX in patients with locally advanced pancreatic cancer

Cancer Research2025-09-28

An open-label, dose-finding, phase Ib study to assess the safety, tolerability of nesuparib (JPI-547), a dual inhibitor of PARP/TNKS, in combination with modified FOLFIRINOX (mFOLFIRINOX) and gemcitabine-nab-paclitaxel (GemAbraxane) in patients with locally advanced and metastatic pancreatic cancer.

Journal of Clinical Oncology2025-05-28

AIRPanc: A phase 2, open-label, multicenter, randomized study evaluating neoadjuvant therapy targeting the adenosine immunosuppressive pathway in combination with immune checkpoint blockade and radiation therapy in patients with advanced pancreatic ductal adenocarcinoma who are candidates for surgical resection.

Journal of Clinical Oncology2024-01-20

Abstract CT246: Phase 1b/2 study of giloralimab in combination with modified FOLFIRINOX with or without budigalimab in patients with untreated metastatic pancreatic cancer

Cancer Research2022-06-15

A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma.

2021-02-164 citations

Chemotherapy-based split stereotactic body radiation therapy for borderline resectable and locally advanced pancreatic cancer: study protocol of a prospective, single-arm phase II trial

BMJ Open2020-11-014 citations

Phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer.

Journal of Clinical Oncology2016-05-2012 citations